Attribution

Data Sources

How Ingryd is built

Ingryd's product information is built on publicly available scientific guidelines and open government data.

Product database

USDA FoodData Central

Nutrition data is provided by the U.S. Department of Agriculture (USDA) FoodData Central database, a publicly available resource maintained by a U.S. federal agency. While we strive for accuracy, product formulations may change. Always verify nutrition information by reading the product label.
fdc.nal.usda.gov

Food scoring systems

Nutri-Score (2023 algorithm)

Santé publique France. Nutri-Score — updated algorithm calculation workbook. Ingryd implements the 2023 revision of the front-of-pack nutrition label used across much of Europe.

Fruit, vegetable and legume estimation

Vergeer L, et al. (2020). Methodology for the Determination of Fruit, Vegetable, Nut and Legume Points for Products Sold in Canadian Grocery Stores. Foods, 9(8), 1127.

GLP-1 nutrition guidance

Joint advisory — ACLM, ASN, OMA, TOS

Mozaffarian D, et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars, 15, 100181. This is the source for the protein guidance Ingryd applies during active weight-loss phases.

Gorgojo-Martínez JJ, et al.

Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine (2023), 12, 145.

Wharton S, et al.

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine (2022), 134(1), 14–19.

Gentinetta S, et al.

Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonists. Diabetes, Metabolic Syndrome and Obesity (2024), 17, 4817–24.

WEGOVY (semaglutide) — Full Prescribing Information

Novo Nordisk / U.S. Food and Drug Administration, revision 10/2025. Used for treatment-phase definitions.

Funding disclosure. The three gastrointestinal-management papers above (Gentinetta, Wharton, Gorgojo-Martínez) are funded by or affiliated with Novo Nordisk, the manufacturer of semaglutide. Together they represent the available published guidance on dietary management of GLP-1 side effects. We cite them because they are the literature that exists, and we disclose the funding because you should weigh it.

Ingryd is not affiliated with, endorsed by, or sponsored by any of the organizations listed above. These sources are cited as the published scientific and regulatory references that inform Ingryd's product information.